| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8787196 | European Journal of Surgical Oncology (EJSO) | 2017 | 22 Pages |
Abstract
CRS/HIPEC is a promising treatment modality for patients with PS. Histological subtype may influence survival. A global prospective registry of patients to further assess the efficacy of CRS/HIPEC is needed.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Armando Sardi, Arkadii Sipok, Dario Baratti, Marcello Deraco, Paul Sugarbaker, George Salti, Yutaka Yonemura, Paolo Sammartino, Olivier Glehen, Naoual Bakrin, Teresa P. DÃaz-Montes, Vadim Gushchin,